Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Adenosine triphosphate may decrease weight loss and improve muscle strength in patients with advanced solid tumors.

PURPOSE: Phase I trial to study the effectiveness of adenosine triphosphate in controlling loss of weight and loss of muscle mass in patients who have advanced solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dartmouth-Hitchcock Medical Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Adenosine

Criteria

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed advanced solid tumor that is not curable by conventional therapy

• Brain metastases allowed if adequately controlled with radiotherapy

PATIENT CHARACTERISTICS:

Age:

• Over 18

Performance status:

• Karnofsky 60-100%

Life expectancy:

• At least 12 weeks

Hematopoietic:

• WBC at least 3,500/mm^3

• Absolute neutrophil count at least 2,000/mm^3

• Platelet count at least 100,000/mm^3

Hepatic:

• SGOT and SGPT no greater than 3 times normal

• Bilirubin no greater than 2.0 mg/dL

Renal:

• Creatinine no greater than 1.5 mg/dL

• Creatinine clearance greater than 60 mL/min

• BUN no greater than 25 mg/dL

Cardiovascular:

• Adequate cardiovascular function

• No congestive heart failure (New York Heart Association class III or IV heart disease)

• No angina pectoris AND/OR

• No significant arrhythmia

• No myocardial infarction within the past 6 months

• No clinically significant ischemic cardiac disease currently under treatment

• No clinically significant conduction system disease in the absence of a pacemaker (e.g., sick sinus syndrome, or second or third degree atrioventricular block)

Pulmonary:

• Adequate pulmonary function

• No clinical evidence of acute chronic obstructive pulmonary disease

• FEV1 at least 50% predicted

• Arterial oxygen tension at least 90% by pulse oximetry and on breathing room air

• No asthma OR

• No evidence of more than 20% reversibility in FEV1 with albuterol therapy

Other:

• Not pregnant or nursing

• Fertile patients must use effective contraception

• No history of severe adverse reaction to adenosine

• No uncontrolled medical illness

• No average daily pain scores of at least 5 on a simple Visual Analogue Self pain assessment (0-10) scale

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered

Endocrine therapy:

• Not specified

Radiotherapy:

• See Disease Characteristics

• At least 3 weeks since prior radiotherapy and recovered

Surgery:

• Not specified

Other:

• At least 30 days since prior investigational therapy

• At least 14 days since prior long-term theophylline, dipyridamole, or dipyridamole/aspirin therapy

• No concurrent long-term theophylline, dipyridamole, or dipyridamole/aspirin therapy

• No concurrent maintenance anti-anginal drug therapy